Adverse Effects Associated With JAK Inhibitors in Myelofibrosis

Overall, BMT CTN 0702 showed no improvement in outcomes with added post-ASCT consolidation as compared to standard lenalidomide maintenance.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

The analysis saw minimal evidence of increased relapse among patients with hematologic cancers and minimal residual disease vs those without.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Researchers from Bambino Gesù Children’s Hospital and Sapienza University in Rome, Italy examined the recovery and function of MAIT cells in pediatric and young adult patients following allo-HSCT.

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.